Archive for October, 2003

GE's Genomic Future

GE’s Genomic Future On its face, General Electric’s $9.5 billion stock purchase of Amersham is about imaging systems. But the more far-reaching consequences of the deal puts GE on the cutting edge of how new knowledge about genetics is used to treat patients. The deal could put General Electric in direct competition with diagnostic and […]


Medicine's Big Bottleneck

Medicine’s Big Bottleneck If health care companies and the U.S. government do not tread carefully, concerns about the cost of developing and providing treatments could derail medical innovation. That was the consensus among top industry and regulatory figures yesterday during speeches and interviews at the Medical Innovations Summit at the Cleveland Clinic.